Endpoints News
Gilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch in
Gilead Sciences is set to enter the T cell engager space in an unusual — perhaps even unprecedented — deal arrangement that involves the pharma budgeting $1.675 billion upfront to buy Ouro Medicines and for Galapagos to …